Clinical trial
Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K…
NCT02227550 · Atrial Fibrillation Network, Other · Completed
Key facts
| NCT number | NCT02227550 |
|---|---|
| Title | Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy |
| Official title | An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation |
| Acronym | AXAFA |
| Lead sponsor | Atrial Fibrillation Network, Other |
| Collaborators | Bristol-Myers Squibb Industry Pfizer Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Vitamin K antagonist, Apixaban |
| Enrollment | 676 |
| Start date | Dec 1, 2014 |
| Primary completion | Apr 1, 2017 |
| Completion | Sep 1, 2017 |
| First posted | Aug 28, 2014 |
| Last update posted | Oct 20, 2017 |
| Countries | Austria, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: